Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Non-Current Assets (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Non-Current Assets for 12 consecutive years, with $11.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets fell 8.56% year-over-year to $11.3 million, compared with a TTM value of $46.1 million through Sep 2025, down 7.54%, and an annual FY2024 reading of $11.8 million, down 6.0% over the prior year.
  • Non-Current Assets was $11.3 million for Q3 2025 at Avalo Therapeutics, down from $11.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $18.4 million in Q4 2021 and bottomed at $11.3 million in Q3 2025.
  • Average Non-Current Assets over 5 years is $15.1 million, with a median of $16.7 million recorded in 2023.
  • The sharpest move saw Non-Current Assets increased 5.75% in 2022, then fell 26.3% in 2024.
  • Year by year, Non-Current Assets stood at $18.4 million in 2021, then dropped by 7.72% to $17.0 million in 2022, then dropped by 25.68% to $12.6 million in 2023, then decreased by 6.0% to $11.8 million in 2024, then dropped by 4.97% to $11.3 million in 2025.
  • Business Quant data shows Non-Current Assets for AVTX at $11.3 million in Q3 2025, $11.4 million in Q2 2025, and $11.6 million in Q1 2025.